Immix Biopharma IncNASDAQ:IMMX
- LAST PRICE1.4700
- TODAY'S CHANGE (%)0.1300 (9.7015%)
- Bid / Lots1.4500/ 21
- Ask / Lots1.4700/ 22
- Open / Previous Close1.3400 / 1.3400
- Day Range
- 52 Week Range
- Volume129,747
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | IMMX |
|---|---|---|
| 09:32 ET | 1551 | 1.34 |
| 09:36 ET | 17534 | 1.3194 |
| 09:39 ET | 2450 | 1.3117 |
| 09:41 ET | 2552 | 1.29 |
| 09:43 ET | 1884 | 1.2601 |
| 09:45 ET | 138 | 1.285 |
| 09:50 ET | 19506 | 1.3 |
| 09:56 ET | 600 | 1.3296 |
| 10:03 ET | 200 | 1.3135 |
| 10:10 ET | 200 | 1.336 |
| 10:17 ET | 7613 | 1.35 |
| 10:19 ET | 1447 | 1.39 |
| 10:21 ET | 1127 | 1.351 |
| 10:26 ET | 200 | 1.36 |
| 10:28 ET | 651 | 1.36 |
| 10:39 ET | 3810 | 1.37 |
| 10:46 ET | 322 | 1.38 |
| 10:57 ET | 5937 | 1.3999 |
| 11:04 ET | 1357 | 1.3976 |
| 11:11 ET | 274 | 1.3701 |
| 11:26 ET | 2393 | 1.3898 |
| 11:40 ET | 1500 | 1.38 |
| 11:44 ET | 100 | 1.4 |
| 11:47 ET | 5000 | 1.3985 |
| 11:51 ET | 300 | 1.385 |
| 12:25 ET | 200 | 1.42 |
| 12:30 ET | 200 | 1.425639 |
| 12:32 ET | 1575 | 1.43 |
| 12:38 ET | 132 | 1.4289 |
| 12:41 ET | 400 | 1.43 |
| 12:43 ET | 100 | 1.435 |
| 12:50 ET | 2307 | 1.445 |
| 12:54 ET | 200 | 1.4451 |
| 12:56 ET | 483 | 1.44 |
| 12:57 ET | 2077 | 1.4499 |
| 01:01 ET | 2100 | 1.445 |
| 01:03 ET | 424 | 1.4495 |
| 01:10 ET | 888 | 1.46 |
| 01:15 ET | 6100 | 1.5 |
| 01:17 ET | 2700 | 1.4851 |
| 01:28 ET | 102 | 1.4898 |
| 01:32 ET | 1000 | 1.5 |
| 01:33 ET | 6788 | 1.49 |
| 01:35 ET | 5500 | 1.48 |
| 01:37 ET | 5211 | 1.46 |
| 02:00 ET | 2384 | 1.46 |
| 02:02 ET | 500 | 1.475 |
| 02:04 ET | 100 | 1.49 |
| 02:06 ET | 1000 | 1.4896 |
| 02:09 ET | 1200 | 1.47 |
Yesterday
DJ Immix Biopharma Price Target Maintained With a $7.00/Share by HC Wainwright & Co., from 7:07AM ET on Thursday Oct 03, 2024 by Dow Jones
7:07AM ET on Thursday Oct 03, 2024 by Dow Jones
Oct 2, 2024
Immix Biopharma Advances CAR-T NXC-201 to Expansion Cohort Dose Level in U.S. AL Amyloidosis Trial NEXICART-2, from 9:32AM ET on Wednesday Oct 02, 2024 by Dow Jones
9:32AM ET on Wednesday Oct 02, 2024 by Dow Jones
Sep 19, 2024
Immix Biopharma Announces Dr. Raymond Comenzo, Internationally Recognized AL Amyloidosis Expert, Director of the Myeloma and Amyloid Program at Tufts Medical Center, Joins Scientific Advisory Board, from 9:31AM ET on Thursday Sep 19, 2024 by Dow Jones
9:31AM ET on Thursday Sep 19, 2024 by Dow JonesImmix Biopharma Announces Dr. Raymond Comenzo, Internationally Recognized AL Amyloidosis Expert, Director of the Myeloma and Amyloid Program at Tufts Medical Center, Joins Scientific Advisory Board, from 9:31AM ET on Thursday Sep 19, 2024 by Dow Jones
9:31AM ET on Thursday Sep 19, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Immix Biopharma Inc | 36.8M | -1.7x | --- |
NextCure Inc | 36.6M | -0.6x | --- |
Passage Bio Inc | 37.1M | -0.5x | --- |
Akari Therapeutics PLC | 36.4M | -1.0x | --- |
Protara Therapeutics Inc | 36.3M | -0.6x | --- |
Onconetix Inc | 37.3M | 0.0x | --- |
Company Information
Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the application of chimeric antigen receptor cell therapy (CAR- T) in light chain (AL) Amyloidosis and autoimmune disease. The Company's lead cell therapy asset is CAR-T NXC-201 for autoimmune disease, relapsed/refractory AL Amyloidosis, and relapsed/refractory multiple myeloma, which is being evaluated in its ongoing Phase Ib/IIa NEXICART-1 (NCT04720313) clinical trial. Its tissue specific therapeutic IMX-110 is in clinical trials as a monotherapy, and in combination with tislelizumab (BeiGene anti-PD-1 - IMMINENT-01 NCT05840835) for advanced solid tumors, such as relapsed/refractory colorectal cancer (CRC). IMX-110 in Phase Ib/IIa clinical trials, is a Tissue-Specific Therapeutic with TME Normalization, a technology that the Company is developing initially for mCRC and Soft Tissue Sarcoma (STS).
Contact Information
- Headquarters
- 11400 West Olympic Blvd., Suite 200LOS ANGELES, CA, United States 90064
- Phone
- 310-651-8041
- Fax
- ---
Executives
- Chairman of the Board, Chief Executive Officer
- Ilya Rachman
- Scientific Co-Founder
- Vladimir Torchilin
- Chief Financial Officer, Director
- Gabriel Morris
- Head - Chemistry, Manufacturing, and Control
- Nandan Oza
- Acting Chief Medical Officer, Head - Clinical Development
- Graham Ross
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $36.8M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 27.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-0.84 |
Book Value | $0.82 |
P/E Ratio | -1.7x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
